The impact of pregnancy on the pharmacokinetics of antidepressants: a systematic critical review and meta-analysis

References

• Westin AA, Reimers A, Spigset O. Should pregnant women receive lower or higher medication doses? Tidsskr Nor Laegeforen. 2018 Oct 30;138(17).
   Google Scholar
• Pariente G, Leibson T, Carls A, et al. Pregnancy-associated changes in pharmacokinetics: a systematic review. PLoS Med. 2016 Nov;13(11):e1002160.
   Google Scholar
• Deligiannidis KM, Byatt N, Freeman MP. Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring. J Clin Psychopharmacol. 2014 Apr;34(2):244–255.
   Google Scholar
• Tasnif Y, Morado J, Hebert MF. Pregnancy-related pharmacokinetic changes. Clin Pharmacol Ther. 2016 Jul;100(1):53–62.
   Google Scholar
• Westin AA. The impact of pregnancy on maternal serum concentrations of antiepileptic, antipsychotic and antidepressant drugs. Evidence from therapeutic drug monitoring. Trodheim: Norwegian University of Science and Technology; 2018.
   Google Scholar
• Sit DK, Perel JM, Helsel JC, et al. Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. J Clin Psychiatry. 2008 Apr;69(4):652–658.
   Google Scholar
• Westin AA, Brekke M, Molden E, et al. Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: changes in drug disposition. PLoS One. 2017;12(7):e0181082.
   Google Scholar
• Sun Y, Dreier JW, Liu X, et al. Trend of antidepressants before, during, and after pregnancy across two decades-A population-based study. Brain Behav. 2019;15:e01441.
   Google Scholar
• Freeman MP, Nolan PE Jr., Davis MF, et al. Pharmacokinetics of sertraline across pregnancy and postpartum. J Clin Psychopharmacol. 2008 Dec;28(6):646–653.
   Google Scholar
• Wisner KL, Perel JM, Wheeler SB. Tricyclic dose requirements across pregnancy. Am J Psychiatry. 1993 Oct;150(10):1541–1542.
   Google Scholar
• Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA. 2006 Feb 1;295(5):499–507.
   Google Scholar
• Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015 Jun 2;162(11):777–784.
   Google Scholar
• Wisner KL, Perel JM, Peindl KS, et al. Effects of the postpartum period on nortriptyline pharmacokinetics. Psychopharmacol Bull. 1997;33(2):243–248.
   Google Scholar
• Heikkinen T, Ekblad U, Kero P, et al. Citalopram in pregnancy and lactation. Clin Pharmacol Ther. 2002 Aug;72(2):184–191.
   Google Scholar
• Schoretsanitis G, Paulzen M, Unterecker S, et al. TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. World J Biol Psychiatry. 2018 Apr;19(3):162–174.
   Google Scholar
• Hiemke C, Bergemann N, HW C, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018 Jan;51(1–02):9–62.
   Google Scholar
• Paulzen M, Stingl JC, Augustin M, et al. Comprehensive measurements of Intrauterine and Postnatal Exposure to Lamotrigine. Clin Pharmacokinet. 2019 Apr;58(4):535–543.
   Google Scholar
• Schoretsanitis G, Spina E, Hiemke C, et al. A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone. Expert Rev Clin Pharmacol. 2017 Sep;10(9):965–981.
   Google Scholar
• Schoretsanitis G, Spina E, Hiemke C, et al. A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone. Expert Rev Clin Pharmacol. 2018 Dec;11(12):1237–1253.
   Google Scholar
• Schoretsanitis G, Spina E, Hiemke C, et al. A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone. Expert Rev Clin Pharmacol. 2018 Jun;11(6):625–639.
   Google Scholar
• Schoretsanitis G, Westin AA, Deligiannidis KM, et al. Excretion of antipsychotics into the amniotic fluid, umbilical cord blood, and breast milk: A systematic critical review and combined analysis. Ther Drug Monit. 2020 Apr;42(2):245–254.
   Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986 Sep;7(3):177–188.
   Google Scholar
• Schwarzer G, Carpenter JR, Rücker G. Meta-Analysis with R. Heidelberg: Springer; 2015.
   Google Scholar
• Kanji S, Hayes M, Ling A, et al. Reporting guidelines for clinical pharmacokinetic studies: the clinpk statement. Clin Pharmacokinet. 2015 Jul;54(7):783–795.
   Google Scholar
• Brogtrop J, Zwarts P, Holleboom CAG, et al. Optimisation of pharmacotherapy for depression during pregnancy. Pilot study for evaluation of existing paroxetine therapy. Pharm Weekbl. 2007;142:34–37.
   Google Scholar
• Kim J, Riggs KW, Misri S, et al. Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding. Br J Clin Pharmacol. 2006 Feb;61(2):155–163.
   Google Scholar
• Ververs FF, Voorbij HA, Zwarts P, et al. Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy. Clin Pharmacokinet. 2009;48(10):677–683.
   Google Scholar
• Sit D, Perel JM, Luther JF, et al. Disposition of chiral and racemic fluoxetine and norfluoxetine across childbearing. J Clin Psychopharmacol. 2010 Aug;30(4):381–386.
   Google Scholar
• Altshuler LL, Hendrick VC. Pregnancy and psychotropic medication: changes in blood levels. J Clin Psychopharmacol. 1996 Feb;16(1):78–80.
   Google Scholar
• Heikkinen T, Ekblad U, Palo P, et al. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther. 2003 Apr;73(4):330–337.
   Google Scholar
• Klier CM, Mossaheb N, Saria A, et al. Pharmacokinetics and elimination of quetiapine, venlafaxine, and trazodone during pregnancy and postpartum. J Clin Psychopharmacol. 2007 Dec;27(6):720–722.
   Google Scholar
• Ter Horst PG, Larmene-Beld KH, Bosman J, et al. Concentrations of venlafaxine and its main metabolite O-desmethylvenlafaxine during pregnancy. J Clin Pharm Ther. 2014 Oct;39(5):541–544.
   Google Scholar
• Ter Horst PG, Proost JH, Smit JP, et al. Pharmacokinetics of clomipramine during pregnancy. Eur J Clin Pharmacol. 2015 Dec;71(12):1493–1500.
   Google Scholar
• Bromek E, Rysz M, Haduch A, et al. Activation of 5-HT1A receptors in the hypothalamic paraventricular nuclei negatively regulates cytochrome p450 expression and activity in rat liver. Drug Metab Dispos. 2018 Jun;46(6):786–793.
   Google Scholar
• Jannuzzi G, Gatti G, Magni P, et al. Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: sources of variability and preliminary observations on relations with clinical response. Ther Drug Monit. 2002 Oct;24(5):616–627.
   Google Scholar
• Xu ZH, Wang W, Zhao XJ, et al. Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N-demethylation of sertraline in human liver microsomes. Br J Clin Pharmacol. 1999 Sep;48(3):416–423.
   Google Scholar
• Wang JS, Zhu HJ, Gibson BB, et al. Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein. Biol Pharm Bull. 2008 Feb;31(2):231–234.
   Google Scholar
• Adhikari K, Patten SB, Lee S, et al. Adherence to and persistence with antidepressant medication during pregnancy: does it differ by the class of antidepressant medication prescribed? Can J Psychiatry. 2019 Mar;64(3):199–208.
   Google Scholar
• Thangaratinam S, Marlin N, Newton S, et al. AntiEpileptic drug Monitoring in PREgnancy (EMPiRE): a double-blind randomised trial on effectiveness and acceptability of monitoring strategies. Health Technol Assess. 2018 May;22(23):1–152.
   Google Scholar
• de Leon J. A critical commentary on the 2017 AGNP consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology. Pharmacopsychiatry. 2018 Jan;51(1–02):63–68.
   Google Scholar
• de Leon J. The future (or lack of future) of personalized prescription in psychiatry. Pharmacol Res. 2009 Feb;59(2):81–89.
   Google Scholar
• Schoretsanitis G, de Leon J, Eap CB, et al. Clinically significant drug-drug interactions with agents for attention-deficit/hyperactivity disorder. CNS Drugs. 2019 Dec;33(12):1201–1222.
   Google Scholar